HIF1A and familial pancreatic carcinoma: Similarly, HS-345, an inhibitor targeting tropomyosin-related kinase A, and HS-527, an inhibitor of PI3K, inhibit angiogenesis via targeting HIF-1α/VEGF axis in pancreatic cancer [95, 96].